Deciduous Therapeutics
PrivateLast Round
VC Round
Mar 1, 2023
Est. Valuation
$45M
Total Funding Raised
$16.35M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Deciduous Therapeutics is a biotechnology company developing novel immunotherapies that activate the endogenous immune mechanism to selectively eliminate senescent cells for the treatment of age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Deciduous Therapeutics Comparables
Compare Deciduous Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rubedo Life Sciences | 87% | |
| Cleara Biotech | 87% | |
| Centenara Labs AG | 82% |
Deciduous Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 1, 2023 | ||||
| Series A | Dec 1, 2022 | ||||
| Grant | Oct 21, 2021 | ||||
| Seed | Jul 10, 2019 | ||||
| Accelerator | Mar 1, 2019 |
Deciduous Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LongGame Ventures | VC Round |
| Bakar Labs | Grant |
| Owl Capital | Series A |
| Gaingels | VC Round |
| age1 | Seed, Accelerator |
| Eisai Innovation | Grant |
| Presight Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 86% MoM.
- Jul 20, 2026
Open roles increased to 16, 133% of headcount.
Deciduous Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Deciduous Therapeutics's valuation, stock price, and market status.
Is Deciduous Therapeutics a public or private company?
Deciduous Therapeutics is a private company.
What is the current stock price of Deciduous Therapeutics?
Deciduous Therapeutics is a private company, so its shares have no public market price. Caplight tracks Deciduous Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Deciduous Therapeutics worth (valuation)?
Deciduous Therapeutics's valuation is estimated at $45.0M based on funding round data.
Can I buy Deciduous Therapeutics stock?
Deciduous Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Deciduous Therapeutics's last funding round?
Deciduous Therapeutics's most recent funding round was VC Round on March 1, 2023.
Who are the main investors in Deciduous Therapeutics?
Key investors in Deciduous Therapeutics include The Longevity Fund.
Will Deciduous Therapeutics IPO soon?
No public IPO plans have been announced for Deciduous Therapeutics.
How can I track Deciduous Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Deciduous Therapeutics's shares on secondary markets.